Applied BioCode Corporation (TPE:6598)

Market Cap	2.41B
Revenue (ttm)	443.69M
Net Income (ttm)	-207.78M
Shares Out	102.81M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,077
Average Volume	180,213
Open	24.00
Previous Close	23.45
Day's Range	23.65 - 24.15
52-Week Range	17.00 - 25.45
Beta	0.74
RSI	55.68
Earnings Date	Mar 15, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6598

Financial Performance

In 2024, Applied BioCode's revenue was 343.07 million, a decrease of -13.18% compared to the previous year's 395.17 million. Losses were -260.81 million, 58.8% more than in 2023.